eligibility_summary
Adults (≥18) with consent, relapsed/refractory mantle cell lymphoma after ≥1 prior regimen including ibrutinib, prior bendamustine allowed if response >1 yr, measurable disease, ECOG 0–2, life expectancy ≥24 wks, adequate organ function (unless disease-related). Exclude severe mAb/bendamustine/rituximab allergy/contraindications, recent trials/therapy/surgery, SCT (allo or auto ≤100 d or eligible), CNS disease, >G1 neuropathy, major comorbidities/infections (HBV/HCV/HIV/HTLV‑1/TB), other recent cancer, pregnancy, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-center, single-arm Phase II trial in relapsed/refractory mantle cell lymphoma testing polatuzumab vedotin + bendamustine + rituximab. Polatuzumab vedotin: antibody-drug conjugate (humanized IgG1 anti-CD79b) linked to MMAE, binds CD79b on B cells (BCR complex), is internalized, and releases MMAE to disrupt microtubules, causing mitotic arrest and apoptosis, may also engage ADCC. Rituximab: chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, complement-dependent cytotoxicity, and direct apoptosis. Bendamustine: alkylating agent (nitrogen mustard) inducing DNA crosslinks and cell death. Target cells/pathways: malignant B cells in MCL, CD79b and CD20 surface antigens, BCR pathway, microtubules (tubulin), DNA integrity, and immune effector mechanisms. Primary endpoint: response rate.